Literature DB >> 23429949

Oncolytic vaccinia virus therapy of salivary gland carcinoma.

Natalya Chernichenko1, Gary Linkov, Pingdong Li, Richard L Bakst, Chun-Hao Chen, Shuangba He, Yong A Yu, Nanhai G Chen, Aladar A Szalay, Yuman Fong, Richard J Wong.   

Abstract

OBJECTIVE: To examine the therapeutic effects of an attenuated, replication-competent vaccinia virus (GLV-1h68) against a panel of 5 human salivary gland carcinoma cell lines.
DESIGN: The susceptibility of 5 salivary gland carcinoma cell lines to infection and oncolysis by GLV-1h68 was assessed in vitro and in vivo.
RESULTS: All 5 cell lines were susceptible to viral infection, transgene expression, and cytotoxic reactions. Three cell lines were exquisitely sensitive to infection by very low doses of GLV-1h68. Orthotopic parotid tumors exhibited more aggressive behavior compared with flank tumors. A single intratumoral injection of GLV-1h68 induced significant tumor regression without observed toxic effects in flank and parotid tumor models; controls demonstrated rapid tumor progression.
CONCLUSION: These promising results demonstrate significant oncolytic activity by an attenuated vaccinia virus for infecting and lysing salivary gland carcinomas, supporting future clinical trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429949      PMCID: PMC4413455          DOI: 10.1001/jamaoto.2013.1360

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  26 in total

Review 1.  Viral oncolysis.

Authors:  John T Mullen; Kenneth K Tanabe
Journal:  Oncologist       Date:  2002

2.  Salivary neoplasms: overview of a 35-year experience with 2,807 patients.

Authors:  R H Spiro
Journal:  Head Neck Surg       Date:  1986 Jan-Feb

3.  Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer.

Authors:  Pingdong Li; Chun-Hao Chen; Sen Li; Babak Givi; Zhenkun Yu; Dmitriy Zamarin; Peter Palese; Yuman Fong; Richard J Wong
Journal:  Head Neck       Date:  2010-11-04       Impact factor: 3.147

Review 4.  Fighting cancer with vaccinia virus: teaching new tricks to an old dog.

Authors:  Yuqiao Shen; John Nemunaitis
Journal:  Mol Ther       Date:  2005-02       Impact factor: 11.454

Review 5.  Modulation of tumor cell response to chemotherapy by the organ environment.

Authors:  I J Fidler; C Wilmanns; A Staroselsky; R Radinsky; Z Dong; D Fan
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

Review 6.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.

Authors:  M C Bibby
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

Review 7.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.

Authors:  L R Kelland
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

8.  Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery.

Authors:  H H Fiebig; A Maier; A M Burger
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

9.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

Review 10.  The response to chemotherapy of a variety of human tumour xenografts.

Authors:  G G Steel; V D Courtenay; M J Peckham
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

View more
  6 in total

1.  Oncolytic Poxviruses.

Authors:  Winnie M Chan; Grant McFadden
Journal:  Annu Rev Virol       Date:  2014-09-01       Impact factor: 10.431

Review 2.  Mechanisms of Perineural Invasion.

Authors:  Richard L Bakst; Richard J Wong
Journal:  J Neurol Surg B Skull Base       Date:  2016-03-10

3.  Inducible gene expression in tumors colonized by modified oncolytic vaccinia virus strains.

Authors:  Jochen Stritzker; Sascha Huppertz; Qian Zhang; Ulrike Geissinger; Barbara Härtl; Ivaylo Gentschev; Aladar A Szalay
Journal:  J Virol       Date:  2014-07-23       Impact factor: 5.103

Review 4.  New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.

Authors:  Kenneth Lundstrom
Journal:  Biologics       Date:  2018-02-09

5.  TrkB-Targeted Therapy for Mucoepidermoid Carcinoma.

Authors:  Vivian P Wagner; Manoela D Martins; Esra Amoura; Virgilio G Zanella; Rafael Roesler; Caroline B de Farias; Colin D Bingle; Pablo A Vargas; Lynne Bingle
Journal:  Biomedicines       Date:  2020-11-24

Review 6.  Oncolytic virotherapy for head and neck cancer: current research and future developments.

Authors:  Akshiv Malhotra; Arun Sendilnathan; Matthew O Old; Trisha M Wise-Draper
Journal:  Oncolytic Virother       Date:  2015-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.